Previous treatments
|
Number of prior DMARDs
|
N = 865
|
0–3, n (%)
|
582 (67.3)
|
>3, n (%)
|
283 (32.7)
|
Number of prior anti-TNF agents
|
N = 865
|
≥2, n (%)
|
429 (49.6)
|
<2, n (%)
|
436 (50.4)
|
Type of biologic agent
|
N = 851
|
Other MOA, n (%)
|
134 (15.8)
|
Anti-TNF agent
|
717 (84.3)
|
Reason for discontinuation of last biologic
|
N = 847
|
Intolerance, n (%)
|
190 (22.4)
|
Primary inefficacy, n (%)a
|
203 (24.0)
|
Secondary inefficacy, n (%)†
|
400 (47.2)
|
Major improvement + other reasons, n (%)
|
54 (6.4)
|
Concomitant therapies
|
Abatacept treatment pattern at initiation
|
N = 865
|
Monotherapy, n (%)
|
201 (23.2)
|
Combination with MTX (± other DMARDs), n (%)
|
483 (55.8)
|
Combination with other DMARDs, n (%)
|
181 (20.9)
|
Corticosteroid treatment pattern at abatacept initiation (versus before initiation)‡
|
N = 865
|
No corticosteroids, n (%)
|
202 (25.4)
|
Continuous use of corticosteroids, n (%)
|
491 (56.8)
|
Stop corticosteroid use, n (%)
|
18 (2.1)
|
Introduction of corticosteroids, n (%)
|
154 (17.8)
|